Fatima Marok

Forschungsgebiet

Physiologie-basierte Pharmakokinetik (PBPK) Modellierung von Arzneistoff-Wechselwirkungen

Lebenslauf

Seit 04/2019: Doktorandin in der Klinischen Pharmazie

01/2019: Approbation zur Apothekerin

12/2018 - 03/2019: Wissenschaftliche Mitarbeiterin in der Klinischen Pharmazie, Universität des Saarlandes, Saarbrücken

05/2018 – 10/2018: Praktisches Jahr in der Landmann Apotheke, Saarbrücken

11/2017 – 04/2018: Praktisches Jahr und Diplomandin in der Klinischen Pharmazie, Universität des Saarlandes, Saarbrücken

10/2013 – 10/2017: Studium der Pharmazie, Universität des Saarlandes, Saarbrücken

07/2013: Abitur, Marie Luise Kaschnitz Gymnasium, Völklingen

Publikationen

Manuskripte

Feick D, Rüdesheim S, Marok FZ, Selzer D, Loer HLH, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug–drug–gene interaction network. CPT Pharmacometrics Syst Pharmacol 2023;00:1-14

Marok FZ, Wojtyniak J-G, Fuhr LM, Selzer D, Schwab M, Weiss J, Haefeli WE, Lehr T. A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug–drug interaction perpetrators. Pharmaceutics. 2023;15(2):679.

Fuhr LM, Marok FZ, Mees M, Mahfoud F, Selzer D, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic model of the CYP3A4 substrate felodipine for drug-drug interaction modeling. Pharmaceutics 2022;14(7):1474.

Türk D, Fuhr LM, Marok FZ, Rüdesheim S, Kühn A, Selzer D, Schwab M, Lehr T. Novel models for the prediction of drug-gene interactions. Expert Opin on Drug Metab Toxicol 2021;17(11):1293-1310.

Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of bupropion and its metabolites in a CYP2B6 drug-drug-gene interaction network. Pharmaceutics 2021;13(3):331.

Fuhr LM, Marok FZ, Hanke N, Selzer D, Lehr T. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and its drug-drug interaction potential: a physiologically based pharmacokinetic modeling approach. Pharmaceutics 2021;13(2):270.

Poster

Marok F, Wojtyniak JG, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine. 28th Population Approach Group Europe (PAGE) meeting, 2019, Stockholm, Sweden.

Marok F, Wojtyniak JG, Schwab M, Lehr T. Optimizing 5-fluorouracil chemotherapy with regard to DPD drug-gene interactions and circadian effects utilizing a physiologically based pharmacokinetic (PBPK) modeling approach. Annual Meeting of the German Pharmaceutical Society (DPhG), 2019, Heidelberg, Germany.